In cirrhotic patients with variceal bleeding, octreotide controlled bleeding in 78% (36/46) versus 59% (24 of 41) with terlipressin plus nitroglycerin (p = 0.064).
In plain wordsIn variceal bleeding, octreotide controlled bleeding in 78% versus 59% with terlipressin plus nitroglycerin (p = 0.064).
- Peptide
- Octreotide
- Outcome
- IncreaseBleeding control at 12 hr
- Study
n = 87
- Comparator
- Terlipressin plus transdermal nitroglycerin
- Outcome group
- Gastrointestinal protection · Gastrointestinal
- Studied dose
- 25 micrograms/hr · intravenous infusion · 12 hrAs given in this study (human).
Measurements
- Bleeding controlled at 12 hr
- 78%
- octreotide group, 36 of 46 patients
- Bleeding controlled at 12 hr
- 59%
- terlipressin plus nitroglycerin group, 24 of 41 patients
Source sentences
At 12 hr, bleeding was controlled in 59% (24 of 41) in group 1 and 78% (36/46) of group 2 patients (Fisher's exact test, p = 0.064).
2 context sentences(design, population, supporting numbers)
Over 16 mo, 87 patients with endoscopically proved active bleeding from esophageal or cardiac varices were enrolled in five centers in France and randomly assigned to receive intravenous terlipressin (2 mg and then 1 mg/4 hr over 24 hr) and transdermal nitroglycerin (10 mg/12 hr over 24 hr) (group 1)
or octreotide (continuous intravenous infusion of 25 micrograms/hr over 12 hr and then 100 micrograms at hr 12 and hr 18 subcutaneously) (group 2).